Drug intelligence / Profile preview

CI-1998

Development stage: Preclinical
Lead developer: CasInvent Pharma
Modality: Small Molecules

Overview

CI-1998 is a preclinical-stage small molecule inhibitor of casein kinase 1 (CK1) being developed by CasInvent Pharma. The drug is targeted toward the treatment of neurodegenerative diseases, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. CI-1998 is part of a portfolio of CK1 inhibitors licensed from Masaryk University, designed to modulate signaling pathways implicated in central nervous system (CNS) disorders. The company is currently seeking strategic partnerships with CNS-focused pharmaceutical companies to advance the development of this asset.

Targets

CSNK1E (Casein kinase I isoform epsilon)CSNK1D (Casein kinase I delta)CK1α (Casein kinase I alpha)

Beyond the preview

Go deeper on CI-1998.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CI-1998.

Explore the full profile